Paquinimod‐hydrogel hybrid microneedle array patch alleviates hypertrophic scar via inhibiting M1 polarization

IF 6.1 2区医学 Q1 ENGINEERING, BIOMEDICAL

Bioengineering & Translational Medicine Pub Date : 2025-03-15 DOI:10.1002/btm2.70016

Zihui Zhang, Peng Wang, Hengdeng Liu, Hanwen Wang, Miao Zhen, Xuefeng He, Suyue Gao, Juntao Xie, Julin Xie

{"title":"Paquinimod‐hydrogel hybrid microneedle array patch alleviates hypertrophic scar via inhibiting M1 polarization","authors":"Zihui Zhang, Peng Wang, Hengdeng Liu, Hanwen Wang, Miao Zhen, Xuefeng He, Suyue Gao, Juntao Xie, Julin Xie","doi":"10.1002/btm2.70016","DOIUrl":null,"url":null,"abstract":"Hypertrophic scar (HS) is one of the most common complications of skin injuries, with a lack of effective therapeutic approaches to date. Most current research has focused on the dysfunction of hypertrophic scar fibroblasts (HSFBs) and dermal vascular endothelial cells (HDVECs), neglecting the crucial role of the inflammatory microenvironment that causes them to be abnormal. In this study, we first discovered and validated that the S100A8/9 specific inhibitor Paquinimod could inhibit macrophage polarization toward M1, and further suppress the proliferation, migration, collagen formation, and angiogenesis of HSFBs and HDVECs in vitro. This mechanism has also been validated in a rat model of HS. Then, we developed a good biocompatibility and penetrability Paquinimod‐Hydrogel Hybrid Microneedle Array Patch (PHMAP) for HS treatment. With the advantages of excellent penetrability, surface sealing, sustained release, and precise uniform distribution, PHMAP exhibited superior therapeutic efficacy over intravenous and intradermal injections. These results suggest that PHMAP can be a promising and advanced solution for HS prevention and therapies.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"19 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/btm2.70016","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertrophic scar (HS) is one of the most common complications of skin injuries, with a lack of effective therapeutic approaches to date. Most current research has focused on the dysfunction of hypertrophic scar fibroblasts (HSFBs) and dermal vascular endothelial cells (HDVECs), neglecting the crucial role of the inflammatory microenvironment that causes them to be abnormal. In this study, we first discovered and validated that the S100A8/9 specific inhibitor Paquinimod could inhibit macrophage polarization toward M1, and further suppress the proliferation, migration, collagen formation, and angiogenesis of HSFBs and HDVECs in vitro. This mechanism has also been validated in a rat model of HS. Then, we developed a good biocompatibility and penetrability Paquinimod‐Hydrogel Hybrid Microneedle Array Patch (PHMAP) for HS treatment. With the advantages of excellent penetrability, surface sealing, sustained release, and precise uniform distribution, PHMAP exhibited superior therapeutic efficacy over intravenous and intradermal injections. These results suggest that PHMAP can be a promising and advanced solution for HS prevention and therapies.

查看原文本刊更多论文

帕喹尼莫德-水凝胶混合微针阵列贴片通过抑制M1极化减轻增生性疤痕

增生性瘢痕（HS）是皮肤损伤最常见的并发症之一，迄今缺乏有效的治疗方法。目前大多数研究都集中在肥厚性瘢痕成纤维细胞（HSFBs）和真皮血管内皮细胞（hdvec）的功能障碍上，而忽视了炎症微环境导致它们异常的关键作用。在本研究中，我们首次发现并验证了S100A8/9特异性抑制剂Paquinimod可以抑制巨噬细胞向M1极化，进一步抑制HSFBs和HDVECs的体外增殖、迁移、胶原形成和血管生成。这一机制在大鼠HS模型中也得到了验证。然后，我们开发了一种具有良好生物相容性和穿透性的Paquinimod - Hydrogel杂交微针阵列贴片（PHMAP）用于治疗HS。PHMAP具有良好的渗透性、表面密闭性、缓释、分布精确均匀等优点，其治疗效果优于静脉和皮内注射。这些结果表明，PHMAP是一种很有前途的、先进的HS预防和治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

8.40

自引率

4.10%

发文量

150

审稿时长

12 weeks

期刊介绍： Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.